Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
6
NCT03672240
Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment
Phase: Phase 1/2
Role: Lead Sponsor
Start: Nov 30, 2018
Completion: Jun 30, 2020